MRNA shares rose as high as 9% during the day, continuing their recent steady climb.

Don’t miss out the latest news, subscribe to LeapRate’s newsletter

Moderna revealed that the vaccine has been designed so that it recognises certain mutations in a person’s Cancer cells, allowing it to then attack them. The company’s data now leads experts to believe that the cancer vaccine may work in other cases apart from its overall target use case of melanoma sufferers. It has confirmed evidence of the activation of patient immune response when using the vaccine, which was found to be safe to use in the trial. The share price suffered a poor year in 2023 but has risen by almost 14% this year.

Moderna CEO Stéphane Bancel was recently quoted as saying:

 There’s a very strong agreement at the highest level between the US government and China government that they want to collaborate on health care.

He confirmed that three of the company’s vaccines are moving into phase three trials.

The post Moderna Jumps 6% On Vaccine News appeared first on LeapRate.